| Autor: |
Enrique Klériga, Fernando Pérez-Zincer, Jacobo Lester |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Hematology & Transfusion International Journal. 9:35-36 |
| ISSN: |
2469-2778 |
| DOI: |
10.15406/htij.2021.09.00249 |
| Popis: |
The oncoprotein BCR-ABL1 helps with the diagnosis and monitoring the therapeutic response in patients with chronic myeloid leukemia. We describe the case of a 70-year-old woman with chronic myeloid leukemia who did not achieve a molecular response after 12 months of treatment. She was then managed with Dasatinib 70 mg orally twice a day until she reached a complete molecular response. She developed pulmonary toxicity probably due to Dasatinib. The dosage was decreased to 70 mg orally once a day. The patient continues with a complete molecular response with less side effects. In chronic myeloid leukemia, as far as we know, there are no previous reports, after a molecular response with Dasatinib 70 mg twice a day, the maintenance of a good molecular control with a single daily dose. This dose may allow a reduction in toxicity with a better quality of life for patients with chronic myeloid leukemia |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
